Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by TNFSF9 is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. Additionally we are shipping TNFSF9 Proteins (36) and TNFSF9 Kits (6) and many more products for this protein.
Showing 10 out of 152 products:
Mouse (Murine) Monoclonal TNFSF9 Primary Antibody for FACS - ABIN2660885
Pollok, Kim, Kwon: Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4. in European journal of immunology 1995
Show all 10 references for ABIN2660885
Mouse (Murine) Monoclonal TNFSF9 Primary Antibody for FACS - ABIN320113
Goodwin, Din, Davis-Smith, Anderson, Gimpel, Sato, Maliszewski, Brannan, Copeland, Jenkins: Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. in European journal of immunology 1993
Human Monoclonal TNFSF9 Primary Antibody for ICC, FACS - ABIN1169256
Gullo, Koh, Pang, Ho, Tan, Schwarz: Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. in PLoS ONE 2010
4-1BBL can restrain effector T cell development, creating a more favorable regulatory T cell to effector cell balance under tolerogenic conditions, and this may be particularly active in mucosal barrier tissues
These results demonstrate that 4-1BBL-engineered DCs can improve CIKs (show TRAF3IP2 Antibodies) cytotoxicity against prostate cancer cells.
these observations suggest that inhibition of the TLR/4 (show TLR4 Antibodies)-1BBL complex formation may be highly efficient in protecting against continued inflammation
4-1BB (show TNFRSF9 Antibodies) mediates the inflammatory responses in obese skeletal muscle by interacting with its ligand 4-1BBL on macrophages.
CD137 (show TNFRSF9 Antibodies)-CD137L interactions mediated via regulation of CyPA (show PPIA Antibodies) contribute to the progression of atherosclerosis.
Data indicate that CD137L deficient mice displayed a variety of immunological dysfunctions.
monocytes interact with iNKT cells to increase expression of 4-1BBL and 4-1BB (show TNFRSF9 Antibodies), and in conjunction with this pathway, maintain their numbers at baseline.
CD137 (show TNFRSF9 Antibodies)-expressing CD4 (show CD4 Antibodies)+ T cells in the bone marrow engage CD137L on hematopoietic progenitor cells, and this CD137L signaling biases hematopoiesis towards myelopoiesis during aging.
TIRAP (show TIRAP Antibodies) and IRAK2 (show IRAK2 Antibodies) are critical for the sustained inflammatory response that is mediated by late-phase signaling by the TLR-4 (show TLR4 Antibodies)-1BBL complex.
Results suggest that CD137L reverse signaling exerts a pro-apoptotic effect by suppressing integrin-mediated survival signals in neural stem cells.
CD137L is overexpressed in non-small cell lung cancer specimens and positive expression of CD137L was associated with better overall survival.
In vitro immunotherapy is described for anti-prostate cancer effects of cytotoxic T lymphocytes induction by recombinant adenovirus mediated PSMA/4 (show PSMA4 Antibodies)-1BBL dendritic cells.
vaccination with recombinant attenuated Salmonella harboring the CEACAM6 and 4-1BBL gene efficiently increased the number of CD3 (show CD3 Antibodies)+CD8 (show CD8A Antibodies)+ TIL (show TLR1 Antibodies) and NK cells, decreased the number of FOXP3 (show FOXP3 Antibodies) cells and inhibited the development of DMH (show DST Antibodies)-induced colorectal cancer
Elevated plasma levels and monocyte-associated expression of CD137 (show TNFRSF9 Antibodies) ligand in patients with acute atherothrombotic stroke
Hence, the targeted combination of IL-15 (show IL15 Antibodies) and 4-BBL (show TP53 Antibodies) in the form of a trifunctional antibody-fusion protein is a promising new approach for cancer immunotherapy.
this is the first study to indicate that this member of the TNF (show TNF Antibodies) superfamily, CD137 (show TNFRSF9 Antibodies), is modulated by SAHA treatment in breast
Data show that TNFR1 (show TNFRSF1A Antibodies) associates with CD137L and is required for CD137L reverse signaling.
CD137L is a novel diagnostic marker of subtypes of non-Hodgkin B-cell lymphomas.
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This transmembrane cytokine is a bidirectional signal transducer that acts as a ligand for TNFRSF9/4-1BB, which is a costimulatory receptor molecule in T lymphocytes. This cytokine and its receptor are involved in the antigen presentation process and in the generation of cytotoxic T cells. The receptor TNFRSF9/4-1BB is absent from resting T lymphocytes but rapidly expressed upon antigenic stimulation. The ligand encoded by this gene, TNFSF9/4-1BBL, has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation. This cytokine has also been shown to be required for the optimal CD8 responses in CD8 T cells. This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction.
, tumor necrosis factor (ligand) superfamily, member 9
, 4-1BB ligand
, tumor necrosis factor ligand superfamily member 9
, homolog of mouse 4-1BB-L
, receptor 4-1BB ligand